In the Randomized Aldactone Evaluation Study (RALES) [37], blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduced the risk of both morbidity and death among patients with severe heart failure. This evidence concerns the gene NR3C2 and heart failure.